6.3 Women's Health

Pregnancy and Lactation Pharmacotherapy

Medication use during pregnancy demands a rigorous clinical calculus balancing optimal maternal disease management with fetal safety. Untreated maternal conditions (e.g., asthma, epilepsy, hypertension, depression) can pose a far greater risk to fetal development than the pharmacotherapy used to manage them. Physiological changes in pregnancy—such as up to a 50% increase in maternal plasma volume, increased GFR causing faster renal drug clearance, and altered hepatic CYP450 enzyme metabolism (e.g., increased CYP3A4, decreased CYP1A2)—frequently require continuous dosage monitoring and adjustments.

The FDA Pregnancy and Lactation Labeling Rule (PLLR)

In 2015, the FDA mandated a paradigm shift, phasing out the traditional A, B, C, D, and X pregnancy risk categories. These legacy letters were heavily criticized for being overly simplistic, implying a false gradation of risk, and lacking clinical context. The modern Pregnancy and Lactation Labeling Rule (PLLR) mandates exhaustive, evidence-based narrative summaries in package inserts across three critical subsections:

1. Pregnancy: Details available data from pregnancy exposure registries, explicit risk summaries (including specific structural abnormalities, miscarriage, fetal mortality rates), and precise clinical considerations for dosage adjustments or adverse maternal/fetal reactions.
2. Lactation: Quantifies the presence and concentration of the drug or its metabolites excreted in human breast milk (often utilizing the milk-to-plasma ratio and relative infant dose), potential adverse effects on the breastfed infant, and pharmacological impacts on maternal milk production.
3. Females and Males of Reproductive Potential: Delivers actionable clinical guidance on necessary pregnancy testing prior to initiation, strict contraception recommendations, and robust data regarding transient or permanent drug-induced infertility.

Teratogenic Medications and Mechanisms

Certain agents are established human teratogens and must be strictly avoided, frequently mandating rigorous Risk Evaluation and Mitigation Strategy (REMS) programs. Key teratogens include:

• Isotretinoin: Triggers severe CNS, cardiovascular, and craniofacial dysmorphisms (microtia). Requires the strict iPLEDGE program.
• ACE Inhibitors and ARBs (e.g., lisinopril, losartan, valsartan): Cause profound fetal renal tubular dysgenesis, leading to severe oligohydramnios (low amniotic fluid), fetal skull hypoplasia, and pulmonary hypoplasia, particularly catastrophic when exposed during the 2nd and 3rd trimesters.
• Warfarin: Readily crosses the placenta, precipitating Fetal Warfarin Syndrome (characterized by severe nasal hypoplasia, stippled bone epiphyses, and CNS defects). LMWH (enoxaparin) is the preferred alternative as its large molecular size prevents placental transfer.
• Valproic Acid: Impairs folate metabolism, triggering high rates of neural tube defects (spina bifida, anencephaly) and long-term dose-dependent impaired cognitive development (reduced IQ).
• Methotrexate: A potent folate antagonist causing neural tube defects, skeletal anomalies, and spontaneous abortion.
• Thalidomide: Historically notorious for causing severe phocomelia (limb malformations).

Contraception Selection and U.S. MEC Criteria

The selection of hormonal contraceptives—whether combined hormonal contraceptives (CHCs) containing both estrogen and a progestin, or progestin-only contraceptives (POCs)—must be individualized using the CDC's U.S. Medical Eligibility Criteria (U.S. MEC) for Contraceptive Use. The U.S. MEC classifies safety into categories: 1 (no restriction), 2 (advantages outweigh risks), 3 (risks usually outweigh advantages), and 4 (unacceptable health risk/absolute contraindication).

Combined Hormonal Contraceptives (CHCs)

CHCs (encompassing combined oral contraceptive pills, transdermal patches, and vaginal rings) function primarily by suppressing the LH surge (inhibiting ovulation), thickening cervical mucus, and thinning the endometrial lining. The estrogen component (typically ethinyl estradiol) stabilizes the endometrium to prevent unscheduled breakthrough bleeding, but it significantly augments hepatic production of clotting factors, thereby increasing the risk of venous thromboembolism (VTE) and stroke.

Absolute Contraindications to Estrogen (U.S. MEC Category 4):

• History of deep vein thrombosis (DVT) or pulmonary embolism (PE)
• History of stroke, TIA, or ischemic heart disease
• Migraine with aura (at ANY age) due to a synergistically unacceptably high risk of ischemic stroke
• Age ≥35 years AND current smoker of ≥15 cigarettes per day
• Current or history of hormone-sensitive breast cancer
• Severe liver disease, viral hepatitis, or hepatic adenoma
• Uncontrolled hypertension (systolic > 160 mmHg or diastolic > 100 mmHg)

Note on Progestins: Some newer progestins like drospirenone exhibit mild potassium-sparing diuretic effects (similar to spironolactone), carrying a slightly higher Vd and a risk of hyperkalemia.

Progestin-Only Contraceptives (POCs)

POCs (e.g., norethindrone "mini-pills", medroxyprogesterone acetate depot injections, etonogestrel subdermal implants, levonorgestrel IUDs) serve as highly effective alternatives when estrogen is contraindicated. They are universally considered safe (MEC Category 1 or 2) for immediate postpartum breastfeeding women, older heavy smokers, patients with uncontrolled hypertension, and patients with migraines with aura. Clinical Pearl: The traditional progestin-only "mini-pill" demands flawless adherence. It must be taken at the exact same hour every day; a delay of merely >3 hours completely compromises efficacy, requiring strict backup contraception (e.g., condoms) for the next 48 hours.

Hormone Replacement Therapy (HRT) in Menopause

HRT remains the gold-standard, most efficacious treatment for vasomotor symptoms of menopause (VMS, e.g., severe hot flashes, night sweats) and the genitourinary syndrome of menopause (e.g., severe vaginal atrophy, dryness, dyspareunia).

HRT Treatment Principles and Safety

• Estrogen Therapy (ET): When administered systemically without a progestin, estrogen aggressively stimulates endometrial proliferation, drastically increasing the risk of endometrial hyperplasia and endometrial adenocarcinoma. Therefore, systemic ET alone is strictly reserved exclusively for women who have undergone a complete hysterectomy (absence of a uterus).
• Estrogen-Progestogen Therapy (EPT): For women with an intact uterus, a progestogen (e.g., medroxyprogesterone acetate, micronized progesterone) MUST be co-administered with systemic estrogen to protect the endometrium and neutralize the cancer risk.
• Route of Administration: Transdermal estrogens (patches, gels, sprays) bypass first-pass hepatic metabolism, mitigating the hepatic synthesis of clotting factors. They are strongly preferred over oral estrogens as they carry a significantly lower risk of VTE and stroke.
• Localized Symptoms: If a patient's symptoms are purely localized to the vagina (e.g., severe dryness or dyspareunia without hot flashes), localized vaginal estrogen (creams, tablets, silastic rings) is the definitive first-line therapy. Because systemic absorption of low-dose vaginal estrogen is negligible, co-administration of a progestogen is unnecessary, even in women with an intact uterus.

Osteoporosis Management

Osteoporosis is a progressive, systemic skeletal disease defined by dramatically low bone mineral density (BMD) and microarchitectural deterioration, leading to bone fragility and severe fracture susceptibility. It is definitively diagnosed by a T-score of -2.5 or lower on a DEXA (Dual-Energy X-ray Absorptiometry) scan, or clinically by a history of a low-trauma fragility fracture (e.g., hip or vertebral fracture). A T-score between -1.0 and -2.4 indicates osteopenia. The FRAX tool is used to calculate the 10-year probability of major osteoporotic fractures to guide therapy initiation in osteopenic patients.

Comprehensive Pharmacological Management

All patients must first optimize foundational bone health through adequate calcium intake (1,000-1,200 mg/day, preferably dietary) and Vitamin D supplementation (800-1,000 IU/day, aiming for serum 25(OH)D levels >30 ng/mL).

• Bisphosphonates (Alendronate, Risedronate, Zoledronic Acid): The cornerstone first-line antiresorptive therapy for most patients. They bind avidly to hydroxyapatite crystals in bone and potently inhibit osteoclast-mediated bone resorption. Oral forms possess dismal bioavailability (<1%) and mandate strict administration protocols: they must be taken first thing in the morning on a completely empty stomach with a full 6-8 oz glass of plain water, and the patient must remain strictly upright for 30-60 minutes to prevent severe esophagitis, ulceration, and strictures. Rare but severe, long-term adverse effects include osteonecrosis of the jaw (ONJ) and atypical subtrochanteric femur fractures. Due to their immense half-life in bone tissue, a "drug holiday" is heavily recommended after 3-5 years of continuous therapy to mitigate these rare risks.
• Denosumab (Prolia): A highly effective monoclonal antibody against RANKL, administered as a subcutaneous injection every 6 months. It powerfully prevents osteoclast maturation and survival. Crucially, its effects are entirely reversible. Discontinuation precipitates a rapid, massive rebound loss of bone density and a severely elevated risk of multiple spontaneous vertebral fractures. Thus, transition to a bisphosphonate or other antiresorptive agent is mandatory upon stopping denosumab.
• Anabolic Agents (Teriparatide, Abaloparatide): Recombinant parathyroid hormone (PTH) analogs that, when given via daily subcutaneous injection, robustly stimulate osteoblastic bone formation. They are reserved for very high-risk patients (e.g., T-score < -3.0 or history of multiple fractures). Due to a theoretical risk of osteosarcoma (seen in rat models), lifetime treatment duration is strictly capped at a maximum of 2 years, followed by sequential therapy with an antiresorptive agent to maintain the newly formed bone mass.